These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 38395797)
1. Noninvasive Evaluation of Tumoral PD-L1 Using a Novel Hu B; Ma X; Shi L; Liu T; Li L; Yao M; Li C; Jia B Mol Pharm; 2024 Apr; 21(4):1977-1986. PubMed ID: 38395797 [TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation and pilot clinical study of [ Ma X; Zhou X; Hu B; Li X; Yao M; Li L; Qin X; Li D; Yao Y; Hou X; Liu S; Chen Y; Wang Z; Zhou W; Li N; Zhu H; Jia B; Yang Z Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3838-3850. PubMed ID: 37555904 [TBL] [Abstract][Full Text] [Related]
3. Noninvasive Imaging of Tumor PD-L1 Expression Using [ Zhang Y; Ding Y; Li N; Wang S; Zhou S; Li R; Yang H; Li W; Qu J Mol Pharm; 2023 Jan; 20(1):690-700. PubMed ID: 36541699 [TBL] [Abstract][Full Text] [Related]
4. A Pretargeted Imaging Strategy for Immune Checkpoint Ligand PD-L1 Expression in Tumor Based on Bioorthogonal Diels-Alder Click Chemistry. Qiu L; Tan H; Lin Q; Si Z; Mao W; Wang T; Fu Z; Cheng D; Shi H Mol Imaging Biol; 2020 Aug; 22(4):842-853. PubMed ID: 31741201 [TBL] [Abstract][Full Text] [Related]
5. Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8 Ertveldt T; Meulewaeter S; De Vlaeminck Y; Olarte O; Broos K; Van Calenbergh S; Bourgeois S; Deprez J; Heremans Y; Goyvaerts C; Staels W; De Smedt S; Dewitte H; Devoogdt N; Keyaerts M; Verbeke R; Barbé K; Lentacker I; Breckpot K Theranostics; 2023; 13(15):5483-5500. PubMed ID: 37908728 [No Abstract] [Full Text] [Related]
6. Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy. Gao H; Wu Y; Shi J; Zhang X; Liu T; Hu B; Jia B; Wan Y; Liu Z; Wang F J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33203663 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and preliminary biological evaluation of a novel Zhu D; Xu X; Zou P; Liu Y; Wang H; Han G; Lu C; Xie M Bioorg Med Chem Lett; 2023 Nov; 96():129496. PubMed ID: 37797805 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. Gainkam LO; Huang L; Caveliers V; Keyaerts M; Hernot S; Vaneycken I; Vanhove C; Revets H; De Baetselier P; Lahoutte T J Nucl Med; 2008 May; 49(5):788-95. PubMed ID: 18413403 [TBL] [Abstract][Full Text] [Related]
9. Novel small Liang Z; Hu X; Hu H; Wang P; Cai J Front Oncol; 2022; 12():1017737. PubMed ID: 36387113 [TBL] [Abstract][Full Text] [Related]
10. Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers. Broos K; Keyaerts M; Lecocq Q; Renmans D; Nguyen T; Escors D; Liston A; Raes G; Breckpot K; Devoogdt N Oncotarget; 2017 Jun; 8(26):41932-41946. PubMed ID: 28410210 [TBL] [Abstract][Full Text] [Related]
11. Early Phase I Study of a Xing Y; Chand G; Liu C; Cook GJR; O'Doherty J; Zhao L; Wong NCL; Meszaros LK; Ting HH; Zhao J J Nucl Med; 2019 Sep; 60(9):1213-1220. PubMed ID: 30796165 [TBL] [Abstract][Full Text] [Related]
12. PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody. Lv G; Sun X; Qiu L; Sun Y; Li K; Liu Q; Zhao Q; Qin S; Lin J J Nucl Med; 2020 Jan; 61(1):117-122. PubMed ID: 31253743 [TBL] [Abstract][Full Text] [Related]
13. Cheng Y; Shi D; Xu Z; Gao Z; Si Z; Zhao Y; Ye R; Fu Z; Fu W; Yang T; Xiu Y; Lin Q; Cheng D Mol Pharm; 2022 Oct; 19(10):3551-3562. PubMed ID: 35244407 [TBL] [Abstract][Full Text] [Related]
14. In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/micro-CT. Vaneycken I; Govaert J; Vincke C; Caveliers V; Lahoutte T; De Baetselier P; Raes G; Bossuyt A; Muyldermans S; Devoogdt N J Nucl Med; 2010 Jul; 51(7):1099-106. PubMed ID: 20554727 [TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of [ Liu T; Wu Y; Shi L; Li L; Hu B; Wang Y; Gao H; Yu X; Zhang X; Zhao H; Wan Y; Jia B; Wang F Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1810-1821. PubMed ID: 35013776 [TBL] [Abstract][Full Text] [Related]
16. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of 99mTc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression. Mitran B; Altai M; Hofström C; Honarvar H; Sandström M; Orlova A; Tolmachev V; Gräslund T Amino Acids; 2015 Feb; 47(2):303-15. PubMed ID: 25425114 [TBL] [Abstract][Full Text] [Related]
18. Preclinical development and characterisation of Wong NC; Cai Y; Meszaros LK; Biersack HJ; Cook GJ; Ting HH; Mottaghy FM Am J Nucl Med Mol Imaging; 2021; 11(3):154-166. PubMed ID: 34234994 [TBL] [Abstract][Full Text] [Related]
19. Shi L; Chen B; Liu T; Li L; Hu B; Li C; Jia B; Wang F Mol Pharm; 2022 Jul; 19(7):2583-2594. PubMed ID: 35696536 [TBL] [Abstract][Full Text] [Related]
20. In Vivo Imaging of the Programmed Death Ligand 1 by González Trotter DE; Meng X; McQuade P; Rubins D; Klimas M; Zeng Z; Connolly BM; Miller PJ; O'Malley SS; Lin SA; Getty KL; Fayadat-Dilman L; Liang L; Wahlberg E; Widmark O; Ekblad C; Frejd FY; Hostetler ED; Evelhoch JL J Nucl Med; 2017 Nov; 58(11):1852-1857. PubMed ID: 28588151 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]